The Immune Deficiency Foundation is warning that pressure from Congress and others to weaken the National Vaccine Injury Compensation Program could undermine vaccine confidence and supply, with clinical consequences for more than 72 million Americans who are immunocompromised or cannot safely receive some vaccines. The group argues that proposals such as the End the Vaccine Carveout Act could increase litigation, raise costs, and delay compensation for legitimate vaccine injuries while increasing infection risk for vulnerable patients who depend on community immunity.

The Move

• Critics are pushing to broaden vaccine-injury claims and roll back VICP’s liability shield for manufacturers, including through the End the Vaccine Carveout Act introduced in Congress.

• VICP was built to provide a streamlined, evidence-based path to compensation for rare vaccine injuries while helping keep vaccines available and affordable at scale.

• The article argues that adding injuries to the Vaccine Injury Table without clear causal evidence could flood the program with unsupported claims and strain its finances.

Why it Matters for Care

• Patients with immune compromise often cannot mount protective responses to vaccines or cannot receive certain live-attenuated products, making high community vaccination rates a frontline clinical protection.

• If vaccine confidence falls further, declining uptake and rising exemptions could translate into more exposure to preventable infections in oncology, transplant, rheumatology, primary care, and pediatric settings.

• Higher vaccine prices or supply instability would hit medically fragile patients hardest because they bear the greatest consequences when herd protection weakens.

Between the Lines

• VICP’s core bargain is political as well as clinical: compensate genuine injuries predictably while limiting open-ended civil litigation that could deter manufacturers.

• The author’s concern is that unsupported claims would not just dilute compensation; they could also signal to the public that vaccines are broadly unsafe, further eroding trust.

• Even if the program avoids insolvency, more claims could mean slower payouts or smaller awards for patients with rare injuries that do meet scientific criteria.

What to Watch

• Whether Congress advances the End the Vaccine Carveout Act or other proposals to narrow manufacturer protections.

• Any moves to expand the Vaccine Injury Table without strong causal evidence, which would likely trigger legal, policy, and public-health debate.

• Whether policymakers instead pursue narrower reforms the author says could strengthen VICP, such as streamlining claims or raising compensation caps.

Source: RealClearHealth